Abstract:Aim: Insulin-like growth factor-1 receptor (IGF-1R) is one of the main members of the tyrosine protein kinase receptor family. This receptor binds insulin-like growth factor-1 (IGF-1) with a high affinity. IGF-1 is a member of a family of proteins involved in mediating growth and development. However, the correlations of IGF-1 and IGF-1R to prognosis and tumor-infiltrating lymphocytes in different cancers remain unclear. Method: This research comprehensively analyzed the expression pattern of IGF-1 and IGF-1R and the influence of IGF-1 and IGF-1R on clinical significance in prognosis prediction among 33 types of malignancies using The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE) databases. The correlation between IGF-1, IGF-1R, and cancer immunity was explored. Results: IGF-1 and IGF-1R displayed inconsistent gene expression levels among diverse cancer cell lines. Typically, high expression level of IGF-1 and IGF-1R was detected in most malignant tumors. High expression of IGF-1 was closely bound up with the unfavorable overall survival (OS) for patients in BLCA, CHOL, and LAML upon Cox and Kaplan-Meier analyses. While high expression of IGF-1R was closely bound up with the unfavorable overall survival (OS) for patients in BLCA, LIHC, and LUAD. Furthermore, high expression level of IGF-1 and IGF-1R were closely connected with high degrees of tumor infiltrates, including CD4+ T cell, dendritic cells, and macrophages. In addition, we found that IGF-1 was commonly positively correlated with the expression of gene markers including LAIR1, ICOS, CD40LG, CTLA4, CD48, CD28, CD200R1, HAVCR2, and CD86. Whereas, IGF-1R was commonly positively correlated with the expression of gene markers including NRP1 and CD276. More importantly, IGF-1 and IGF-1R expression were correlated with tumor mutation burden (TMB), microsatellite instability (MSI), mismatch repair (MMR), and DNA methyltransferase (DNMT) of different types of cancers. Conclusions: The impact of high IGF-1 and IGF-1R on prognosis and immune infiltrates differs across cancer types. Anti-IGF-1R therapy may inhibit tumor growth and contribute to immunotherapy in LIHC and KIRC.

Supplementary Tables 1-2 from Genomic and Molecular Characterization of Malignant Peripheral Nerve Sheath Tumor Identifies the IGF1R Pathway As a Primary Target for Treatment

Genomic And Molecular Characterization Of Malignant Peripheral Nerve Sheath Tumor Identifies The Igf1r Pathway As A Primary Target For Treatment (Publication With Expression Of Concern. See Vol. 25, Pg. 3195, 2019)

Supplementary Table 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Retraction Note: Genomic Amplification and High Expression of EGFR Are Key Targetable Oncogenic Events in Malignant Peripheral Nerve Sheath Tumor.

Supplementary Tables 1-3, Figures 1-3 from Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134

Supplementary Data from Array-Based Comparative Genomic Hybridization Identifies <i>cdk4</i> and <i>foxm1</i> Alterations As Independent Predictors of Survival in Malignant Peripheral Nerve Sheath Tumor

Prognostic Roles for Fibroblast Growth Factor Receptor Family Members in Malignant Peripheral Nerve Sheath Tumor

Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy.

Functional Investigation of IGF1R Mutations in Multiple Myeloma

Supplementary Table from Mir-205 Targets PTEN and PHLPP2 to Augment AKT Signaling and Drive Malignant Phenotypes in Non–Small Cell Lung Cancer

Oncogenic State and Cell Identity Combinatorially Dictate the Susceptibility of Cells within Glioma Development Hierarchy to IGF1R Targeting

Pan-Cancer Analysis of IGF-1 and IGF-1R as Potential Prognostic Biomarkers and Immunotherapy Targets

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

[Targeted Therapy for Malignant Peripheral Nerve Sheath Tumor: Translational Research and Clinical Application].

Table S8 from Activation of PI3K/AKT Pathway is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer

Insulin-like growth factor 2 targets IGF1R signaling transduction to facilitate metastasis and imatinib resistance in gastrointestinal stromal tumors

387 Pathogenicity of a CCDC6-RET Fusion in Malignant Peripheral Nerve Sheath Tumor (MPNST)

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

EP1.03-35 Prevalence, Clinicopathologic Characteristics, and Molecular Associations of IGF1R Mutations in East Asian Patients with NSCLC

Supplementary Table 2 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis